BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25739586)

  • 1. Effects of rapid-acting insulin analogues insulin glulisine and insulin aspart on postprandial glycemic excursion with single bout of exercise in patients with type 2 diabetes.
    Tanaka N; Hiura Y
    Endocr J; 2015; 62(5):411-6. PubMed ID: 25739586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of insulins glulisine and aspart on postprandial glycemia after a high-glycemic index meal in children with type 1 diabetes.
    Dzygalo K; Szypowska A
    Eur J Endocrinol; 2014 Apr; 170(4):539-45. PubMed ID: 24412929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
    Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
    Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections.
    Cemeroglu AP; Kleis L; Wood A; Parkes C; Wood MA; Davis AT
    Endocr Pract; 2013; 19(4):614-9. PubMed ID: 23425652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF; Zhao LB; Li XY; Wang WQ; Sun SY; Chen YH; Hong J; Su TW; Liu JM; Ning G
    Chin Med J (Engl); 2007 Oct; 120(19):1700-3. PubMed ID: 17935674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes.
    Gallagher A; Home PD
    Diabetes Res Clin Pract; 2005 Mar; 67(3):196-203. PubMed ID: 15713351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes.
    Herz M; Profozic V; Arora V; Smircic-Duvnjak L; Kovacevic I; Boras J; Campaigne BN; Metelko Z
    Curr Med Res Opin; 2002; 18(4):188-93. PubMed ID: 12201618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
    Schwartz S; Zagar AJ; Althouse SK; Pinaire JA; Holcombe JH
    Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes.
    Bolli GB; Luzio S; Marzotti S; Porcellati F; Sert-Langeron C; Charbonnel B; Zair Y; Owens DR
    Diabetes Obes Metab; 2011 Mar; 13(3):251-7. PubMed ID: 21205115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
    Luzio S; Peter R; Dunseath GJ; Mustafa L; Owens DR
    Diabetes Res Clin Pract; 2008 Feb; 79(2):269-75. PubMed ID: 18164094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The comparison of insulin aspart and human soluble insulin used in insulin pump therapy in newly diagnosed type 2 diabetic patients].
    Li YB; Liu J; Liao ZH; Liao Y; Deng WP; Weng JP
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2472-6. PubMed ID: 16321271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intensified insulin therapy of type 2 diabetes mellitus: pre- or postprandial injection of aspart insulin?].
    Jungmann E
    Dtsch Med Wochenschr; 2005 May; 130(20):1254-7. PubMed ID: 15889321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions.
    Ando H; Kurita S; Shimizu A; Kato K; Ishikura K; Taji K; Uno M; Takeshita Y; Misu H; Fujimura A; Kaneko S; Takamura T
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):528-34. PubMed ID: 22642657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
    Schmoelzer I; de Campo A; Pressl H; Stelzl H; Dittrich P; Oettl K; Wascher TC
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):176-81. PubMed ID: 15789278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes.
    Turner D; Luzio S; Gray BJ; Bain SC; Hanley S; Richards A; Rhydderch DC; Martin R; Campbell MD; Kilduff LP; West DJ; Bracken RM
    Diabet Med; 2016 Apr; 33(4):506-10. PubMed ID: 26220149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.